The pathophysiology of hypertensive acute heart failure

Heart

Volumn 101, Issue 23, 2015, Pages 1861-1867

  Viau, David M ^a   Sala Mercado, Javier A ^a   Spranger, Marty D ^a   O'Leary, Donal S ^a   Levy, Phillip D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ARRESTIN; CINACIGUAT; CLEVIDIPINE; GLYCERYL TRINITRATE; NESIRITIDE; NEUROHORMONE; NICARDIPINE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PLACEBO; SERELAXIN; TRV 027; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL COMPLIANCE; BODY FLUID; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DISEASE PREDISPOSITION; EXERCISE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART WORK; HORMONE ACTION; HUMAN; HYPERTENSION; HYPERTENSIVE ACUTE HEART FAILURE; HYPERVOLEMIA; HYPOTENSION; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPATHETIC TONE; VASOCONSTRICTION; ACUTE DISEASE; CAUSALITY; COMPLICATION; DRUG EFFECTS; HEART FAILURE; HEMODYNAMICS; MEDICATION THERAPY MANAGEMENT;

ACUTE DISEASE; CAUSALITY; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION; MEDICATION THERAPY MANAGEMENT; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84948689356     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-307461     Document Type: Article

References (30)

1. Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims. Circulation 2010;122:1975-96.
2. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin 2008;4:23-36.
3. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-9.
4. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 2007;50:144-52.
5. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am Heart J 2014;167:529-36.
6. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
7. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005;96:11G-7G.
8. Ooi H, Chung W, Biolo A. Arterial stiffness and vascular load in heart failure. Congest Heart Fail 2008;14:31-6.
9. Sunagawa K, Maughan WL, Burkhoff D, et al. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983;245: H773-80.
10. Starling MR. Left ventricular-Arterial coupling relations in the normal human heart. Am Heart J 1993;125:1659-66.
11. Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age-And gender-related ventricular-vascular stiffening a community-based study. Circulation 2005;112:2254-62.
12. O'Rourke MF. Arterial aging: pathophysiological principles. Vasc Med 2007;12:329-41.
13. Lorell BH, Carabello BA. Left ventricular hypertrophy pathogenesis, detection, and prognosis. Circulation 2000;102:470-9.
14. Fox JM, Maurer MS. Ventriculovascular coupling in systolic and diastolic heart failure. Curr Cardiol Rep 2006;8:232-9.
15. Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012;59:442-51.
16. O'Leary DS. Altered reflex cardiovascular control during exercise in heart failure: animal studies. Exp Physiol 2006;91:73-7.
17. Colombo PC, Onat D, Sabbah HN. Acute heart failure as "acute endothelitis"-Interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008;10:170-5.
18. Yu C-M, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112:841-8.
19. McEniery CM, Wallace S, Mackenzie IS, et al. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004;24:969-74.
20. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010;56:1071-8.
21. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013;8:Cd005151.
22. Coutsos M, Sala-Mercado JA, Ichinose M, et al. Muscle metaboreflex-induced coronary vasoconstriction limits ventricular contractility during dynamic exercise in heart failure. Am J Physiol Heart Circ Physiol 2013;304:H1029-37.
23. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
24. Franciosa JA, Taylor AL, Cohn JN, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8:128-35.
25. Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2009;14:299-307.
26. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
27. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
28. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
29. Mitrovic V, Seferovic PM, Simeunovic D, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006;27:2823-32.
30. Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 2012;14:1056-66.